News
IMUX
2.870
+11.67%
0.300
Immunic adds 14% as Wedbush initiates with bullish view on lead asset
Seeking Alpha · 3d ago
Wedbush Assumes Immunic at Outperform, Announces Price Target of $5
Benzinga · 4d ago
Wedbush Reaffirms Their Buy Rating on Immunic (IMUX)
TipRanks · 4d ago
Wedbush Assumes Coverage of Immunic With Outperform Rating, Lowers Price Target to $5 From $7
Wedbush Assumes Coverage of Immunic With Outperform Rating, Lowers Price Target to $5 From $7
MT Newswires · 4d ago
Immunic: Revisiting A 'Lottery Ticket'
Seekingalpha · 12/28/2022 14:16
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 12/15/2022 21:32
BARK And 3 Other Stocks Under $2 Insiders Are Aggressively Buying
Benzinga · 11/28/2022 13:29
Immunic President, CEO Buys 8K Shares At Average Price Of $1.35/Share
Benzinga · 11/23/2022 15:16
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 11/17/2022 13:07
Immunic Touts Positive Vidofludimus Calcium Data In Multiple Sclerosis Candidate
Benzinga · 11/17/2022 13:04
BRIEF-Immunic Reports New Data Mid-Stage Trial For Multiple Sclerosis Drug
Reuters · 11/17/2022 12:17
Immunic Reports New Data From Phase 2 EMPhASIS Trial Of Vidofludimus Calcium In Relapsing-Remitting Multiple Sclerosis Supporting The Drug's Neuroprotective Potential
Benzinga · 11/17/2022 11:31
Recap: Immunic Q3 Earnings
Benzinga · 11/03/2022 10:59
BRIEF-Immunic, Inc. Reports Third Quarter 2022 Financial Results
Reuters · 11/03/2022 10:43
Immunic GAAP EPS of -$0.69 misses by $0.03
Seekingalpha · 11/03/2022 10:37
Immunic Q3 EPS $(0.69) Misses $(0.66) Estimate. $72.8M In Cash And Cash Equivalents
Benzinga · 11/03/2022 10:33
Immunic, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced financial results for the third quarter ...
PR Newswire · 11/03/2022 10:30
-- Earnings Flash (IMUX) IMMUNIC Reports Q3 Loss $-0.69, vs. Street Est of $-0.70
-- Earnings Flash (IMUX) IMMUNIC Reports Q3 Loss $-0.69, vs. Street Est of $-0.70
MT Newswires · 11/03/2022 06:52
Immunic's Earnings Outlook
Benzinga · 11/02/2022 18:45
BRIEF-Immunic, Inc. To Announce Financial Results For The Third Quarter Ended September 30, 2022, And Provide Corporate Update
Reuters · 10/27/2022 10:31
More
Webull provides a variety of real-time IMUX stock news. You can receive the latest news about Immunic Inc through multiple platforms. This information may help you make smarter investment decisions.
About IMUX
Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is focused on three development programs. These include the vidofludimus calcium (IMU-838) program, which is focused on the development of oral formulations of a small molecule inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH); the IMU-935 program, which is focused on an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated (RORyt), an immune cell-specific isoform of RORy; and the IMU-856 program, which involves the development of a drug targeting the restoration of intestinal barrier function and regeneration of bowel epithelium. These product candidates are being developed to address diseases such as multiple sclerosis (MS), psoriasis and gastrointestinal diseases.